[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Huashan Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":624},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,78,0,25,[9,43,67,97,125,148,170,204,229,255,280,301,332,360,379,398,414,435,454,478,503,524,547,572,598],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100607193","phase-2-orelabrutinib-combined-with-teniposide-rituximab-and-methotrexate-for-newly-diagnosed-pcnsl-100607193",false,"NCT07185373","Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL","Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed Primary Central Nervous System Lymphoma-A Randomized Controlled Trial","Inclusion Criteria:\n\n* No prior systemic treatment for primary central nervous system lymphoma\n* Pathologically confirmed as diffuse large B-cell lymphoma subtype; with sufficient residual surgical specimens remaining after meeting the needs for pathological diagnosis and preservation\n* Aged 18-75 years (inclusive)\n* ECOG performance status ≤3\n* Expected survival time exceeding 3 months\n* Major organ functions meeting the following standards:\n\n  1. Blood routine parameters (without growth factor support or blood transfusion within the past 7 days; 14 days for pegylated myeloid growth factors): absolute neutrophil count (ANC) ≥1.0×10⁹\u002FL, platelet count (PLT) ≥75×10⁹\u002FL, hemoglobin (Hb) ≥80g\u002FL;\n  2. Blood biochemistry: total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN) or ≤3×ULN (for confirmed Gilbert syndrome with direct bilirubin within normal range); aspartate transaminase (AST) or alanine transaminase (ALT) ≤2.5×ULN; serum creatinine within normal range; estimated glomerular filtration rate (eGFR) ≥70ml\u002Fmin;\n  3. Coagulation function: international normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤1.5×ULN;\n* Ability to tolerate lumbar puncture and\u002For having an indwelling Ommaya reservoir\n* Peripheral blood flow cytometry showed no clonal B cells and no other extramedullary lesions.\n* Voluntary signing of a written informed consent form by the participant or their legal representative prior to trial screening, indicating their understanding of the study purpose, necessary procedures, and willingness to comply with the protocol and attend follow-up visits\n\nExclusion Criteria:\n\n* Lymphoma involving sites outside the central nervous system (CNS)\n* Patients with a previous history of tumors\n* Patients with intraocular lymphoma or suspected diagnosis of intraocular lymphoma invasion\n* Uncontrolled or significant cardiovascular diseases, including:\n\n  1. New York Heart Association (NYHA) class Ⅲ-Ⅳ congestive heart failure, unstable angina, myocardial infarction within 6 months prior to the first administration of study drugs; clinically significant or treatment-requiring arrhythmias at screening; left ventricular ejection fraction (LVEF) \\\u003C50%; or patients with controlled coronary heart disease who are either not using anticoagulants\u002Fantiplatelet drugs or taking 2 or more anticoagulants\u002Fantiplatelet drugs orally.\n  2. Primary cardiomyopathy (e.g., dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, unclassified cardiomyopathy).\n  3. A history of clinically significant QTc interval prolongation, or QTc interval (calculated via Bazett's formula using manually collected screening data) \\>470ms in females or \\>450ms in males.\n  4. Refractory hypertension (blood pressure not controlled despite ≥1 month of optimal, tolerable doses of 2 or more antihypertensive drugs \\[including diuretics\\] with lifestyle modifications; or blood pressure controlled only with 3 or more antihypertensive drugs).\n* Active bleeding within 2 months prior to screening; use of anticoagulants\u002Fantiplatelet drugs for \\\u003C6 months; or a definite bleeding tendency as judged by the investigator (e.g., bleeding-risk esophageal varices, active local ulcer lesions).\n* Diabetic patients whose blood sugar remains poorly controlled after insulin treatment\n* A history of stroke or intracranial hemorrhage within 6 months prior to screening, excluding postoperative sequelae-related intracranial hemorrhage\n* A history of organ transplantation or allogeneic bone marrow transplantation\n* Surgical procedures within 6 weeks prior to screening (diagnostic examinations are not considered surgical procedures; insertion of vascular access devices is exempt from this exclusion criterion).\n* Use of Chinese herbal medicines with anti-tumor effects (as specified in the package insert, e.g., Compound Cantharidin Capsules) within 4 weeks prior to screening\n* Active or uncontrolled hepatitis B virus (HBV) infection (HBsAg positive and\u002For HBcAb positive with positive HBV DNA titer); HCV Ab positive; HIV positive. The following patients can be provisioned for continuous observation pending enrollment when given prophylactic anti-HBV (such as entecavir or tenofovir), including :\n\n  1. HBsAg positive with negative HBV DNA titer.\n  2. HBsAg negative, HBsAb negative, HBcAb positive, and negative HBV DNA titer Patients with positive HBV-DNA can be considered for enrollment only when the HBV-DNA value is less than 500IU\u002FmL after treatment\n* Uncontrolled active systemic fungal, bacterial, viral, or other infections (defined as persistent infection-related symptoms\u002Fsigns that do not improve despite appropriate antibiotic or other treatments) or requiring intravenous antibiotics\n* Administration of live vaccines or immunological agents within 4 weeks prior to enrollment.\n* Need for concurrent and continuous use of drugs with moderate\u002Fstrong inhibitory or inductive effects on cytochrome P450 CYP3A.\n* Patients with hypersensitivity to orelabrutinib or its excipients (e.g., immediate or accelerated allergic reactions).\n* Patients with hypersensitivity to teniposide or its excipients (e.g., immediate or accelerated allergic reactions)\n* Clinically significant gastrointestinal abnormalities that may affect drug intake, transit, or absorption (e.g., inability to swallow, chronic diarrhea, intestinal obstruction, etc.), or participants with total gastrectomy.\n* Participants with a history or current presence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia with severely impaired lung function, etc\n* Participants with chronic liver damage, severe fatty liver, or alcoholic liver disease.\n* Pregnant or lactating women; women of childbearing age who are unwilling to use contraception from the time of enrollment until 180 days after the last dose of the study drug (serum pregnancy test results must be negative within 14 days before the start of study drug treatment for women of childbearing potential); men who are not surgically sterilized and unwilling to use contraception during the study and until 180 days after the last dose of the study drug.\n* Presence of life-threatening diseases or severe organ dysfunction, deemed unsuitable for participation in the trial by the investigator.\n* Any mental or cognitive impairment that may limit the understanding and execution of the informed consent form or adherence to the study\n* Previous receipt of whole-brain radiotherapy for primary central nervous system lymphoma.","ALL","18 Years","75 Years",{"count":21,"type":22},215,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE2","PHASE3","This is a three-arm, multicenter, randomized controlled trial. Eligible participants will be randomized to one of three induction regimens via stratified block randomization at a 2:2:1 ratio.\n\nInduction regimens:\n\nArm A: Teniposide + orelabrutinib + rituximab + methotrexate (MTX) + dexamethasone, administered in 21-day cycles.\n\nArm B: Orelabrutinib + rituximab + MTX + dexamethasone, administered in 21-day cycles.\n\nArm C: Rituximab + MTX + dexamethasone, administered in 21-day cycles. Participants achieving complete response (CR) or unconfirmed complete response (CRu) post-induction will proceed to consolidation therapy, with options including: MTX + rituximab (once every 3 months for 1 year); high-dose chemotherapy followed by autologous stem cell transplantation (ASCT); dose-reduced whole brain radiotherapy; or other modalities (as determined by the investigator).",[29],"Primary Central Nervous System Lymphoma","RECRUITING","2026-08-18",{"date":33,"type":34},"2026-08-19","ACTUAL",{"date":36,"type":34},"2025-10-01",{"date":38,"type":22},"2029-07-30",{"name":40,"class":41},"Huashan Hospital","OTHER",15,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":53,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100644819","exploratory-study-on-infection-and-immunosenescence-based-on-an-elderly-clinical-cohort-100644819","NCT07672522","Exploratory Study on Infection and Immunosenescence Based on an Elderly Clinical Cohort","Inclusion Criteria for the Healthy Control Group\n\n1. No clinical symptoms suggestive of infection, including fever, cough, dyspnea, fatigue, or myalgia.\n2. No abnormal physical signs, including lymphadenopathy, hepatomegaly, splenomegaly, or skin rash.\n3. Normal laboratory test results, including complete blood count (CBC), C-reactive protein (CRP), and liver and renal function tests.\n4. Healthy adults without underlying chronic diseases, no history of infectious diseases within the previous 6 months, and generally normal cognitive function.\n5. Male or female.\n6. Able to understand the study procedures and voluntarily provide written informed consent.\n\nInclusion Criteria for the Infection Group 1.Age: 60 years or older; no gender restrictions. 2. Clinically diagnosed with an infectious disease by the treating physician. 3. The participant provides informed consent and signs the relevant documents.\n\n\\-------------- Exclusion Criteria for the Healthy Control Group\n\n1. Refusal to participate in the study;\n2. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for enrollment.\n\nExclusion Criteria for the Infection Group\n\n1. Final primary diagnosis is a non-infectious disease (e.g., connective tissue disease, tumor, or other conditions).\n2. Positive culture results are determined by the clinician to be due to colonization or contamination rather than infection.\n3. Refusal to participate in the study.\n4. Patients in critical or severe conditions who are unable to cooperate with sample collection.\n5. Other conditions deemed unsuitable for inclusion as determined by the researchers.",true,"60 Years",{"count":52,"type":22},484,"5 Years","OBSERVATIONAL","This prospective observational cohort study aims to investigate the relationship between immunosenescence and infectious diseases in older adults. Individuals aged 60 years and older, including elderly patients with infections and healthy controls, will be enrolled and followed longitudinally.\n\nClinical information, laboratory test results, and health assessment data will be collected. Biological specimens, including peripheral blood, urine, stool, sputum, and nasopharyngeal swabs, will be obtained during enrollment and follow-up. Participants will undergo regular assessments of health status, infection events, and aging-related clinical characteristics.\n\nThe study will evaluate age-related changes in immune function, immune cell composition, immune receptor repertoires, epigenetic characteristics, metabolic profiles, and respiratory and gut microbiota. By integrating clinical and multi-omics data, the study aims to identify biomarkers associated with immunosenescence, susceptibility to infection, disease severity, and clinical outcomes in older adults.\n\nThe results are expected to improve understanding of the mechanisms linking aging, immune dysfunction, and infectious diseases, and to support the development of predictive models and preventive strategies for infection management and healthy aging in elderly populations.",[57],"Immunosenescence","2026-08-02",{"date":60,"type":34},"2026-08-04",{"date":62,"type":34},"2024-11-29",{"date":64,"type":22},"2029-10-30",{"name":40,"class":41},1,{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":12,"sex":17,"minAge":74,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":23,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":66},"100650057","phase-4-niaoduqing-granules-in-older-adults-with-impaired-kidney-function-100650057","NCT07741292","Niaoduqing Granules in Older Adults With Impaired Kidney Function","A Study of the Clinical Benefits of Niaoduqing Granules in Older Adults With Impaired Renal Function","Inclusion Criteria:\n\n1. Participants with stage 3 to 5 chronic kidney disease who are not receiving dialysis.\n2. Age older than 60 years.\n3. The participant or a family member has sufficient literacy and is able to comply with dietary diary recording and other study-related examinations.\n4. The underlying cause of chronic kidney disease is clinically stable.\n\nExclusion Criteria:\n\n1. Malignancy, severe cardiovascular disease, osteoporosis, or severe hematopoietic system disease.\n2. Active infection, defined as C-reactive protein greater than 10 mg\u002FL, or current use of nephrotoxic medications.\n3. Limb paralysis or major limb impairment.\n4. Use of immunosuppressive therapy, including cyclosporine or tacrolimus, within the 3 months before cohort enrollment, or use of corticosteroids at a dose equivalent to more than 10 mg\u002Fday of prednisone.\n5. Severe gastrointestinal disease affecting nutrient absorption.\n6. Current participation in, or participation within the previous month in, another study related to diet or medication.\n7. Known allergy to Niaoduqing Granules.\n8. Any condition that, in the investigator's judgment, makes the participant unsuitable for the study.","61 Years",{"count":76,"type":22},300,[78],"PHASE4","This prospective real-world study will evaluate the clinical benefits of Niaoduqing Granules in older adults with impaired kidney function. Approximately 300 participants aged over 60 years with stage 3 to 5 chronic kidney disease who are not receiving dialysis will be enrolled at Huashan Hospital, Fudan University. The study will examine whether treatment with Niaoduqing Granules is associated with slower kidney function decline and improvements in nutrition, frailty, and other health outcomes.\n\nParticipants will receive 5 g of Niaoduqing Granules three times daily after meals for 12 months, while continuing their usual treatment for chronic diseases as directed by their physicians. Kidney function, laboratory results, nutritional status, frailty, cardiovascular and cerebrovascular events, and survival will be assessed during follow-up. Blood, urine, and stool samples will also be collected to study changes in gut microorganisms and blood metabolites that may help explain how Niaoduqing Granules affect health. Participants will be followed for up to 60 months.",[81],"Chronic Kidney Disease",[83,84,85,86,87,88],"Niaoduqing Granules","Older Adults","Non-Dialysis-Dependent Chronic Kidney Disease","Renal Function Decline","Frailty","Malnutrition","2026-07-28",{"date":91,"type":34},"2026-08-03",{"date":93,"type":34},"2025-12-01",{"date":95,"type":22},"2030-11-30",{"name":40,"class":41},{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":107,"conditions":108,"keywords":112,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":66},"100650007","real-world-study-of-enarodustat-for-anemia-in-non-dialysis-ckd-patients-100650007","NCT07741279","Real-World Study of Enarodustat for Anemia in Non-Dialysis CKD Patients","Real-World Research on Efficacy of Enarodustat in Patients With CKD-Associated Anemia","Inclusion Criteria:\n\n1. Aged 18-85 years, male or female;\n2. CKD-EPI eGFR \\\u003C60 mL\u002Fmin\u002F1.73m², stage 3-5 non-dialysis chronic kidney disease;\n3. Baseline hemoglobin ≥70 g\u002FL and \\\u003C110 g\u002FL, diagnosed with CKD-associated anemia;\n4. No plan for dialysis or kidney transplant within 24 weeks;\n5. Voluntary participation and signed written informed consent.\n\nExclusion Criteria:\n\n1. Severe infection, acute kidney injury, myocardial infarction, stroke, decompensated heart failure within recent 3 months;\n2. Malignancy, severe liver dysfunction (AST\u002FALT\\>2.5 ULN, total bilirubin\\>1.5 ULN), multiple organ failure;\n3. Autoimmune disease (lupus, vasculitis, rheumatoid arthritis) or chronic persistent infection (tuberculosis, fungal infection);\n4. Pregnant or breastfeeding women;\n5. Other causes of anemia (aplastic anemia, myelodysplastic syndrome, hemolytic anemia, active gastrointestinal bleeding);\n6. Poor compliance judged by investigator, unable to complete scheduled follow-up.","85 Years",{"count":106,"type":22},90,"This is a single-center, prospective real-world observational study aiming to evaluate the efficacy and safety of oral enarodustat in adult non-dialysis chronic kidney disease (ND-CKD) patients with renal anemia. A total of 90 eligible participants will be enrolled and stratified into three groups according to baseline C-reactive protein (CRP) levels: CRP ≤3 mg\u002FL, 3\\\u003CCRP ≤10 mg\u002FL, and CRP\\>10 mg\u002FL. All subjects receive routine oral enarodustat treatment with individualized dose titration, together with standard supportive care for CKD. Each participant will be followed up every 4 weeks for a total of 24 weeks. The primary objective is to compare the change in hemoglobin from baseline to week 24 across different inflammation subgroups. Secondary objectives include analyzing dynamic changes of iron metabolism indicators and documenting all adverse events during treatment. This study will explore the optimal individualized dosing strategy of enarodustat under different inflammatory and iron status.",[109,110,111],"Anemia of Chronic Kidney Disease","CKD","Non-dialysis Chronic Kidney Disease",[113,114,115,116,117,118],"Enarodustat","HIF-PHI","Renal anemia","Inflammation","Real-world study","Iron metabolism",{"date":91,"type":34},{"date":121,"type":34},"2025-03-23",{"date":123,"type":22},"2027-12-31",{"name":40,"class":41},{"id":126,"slug":127,"hasResults":12,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":147},"100587045","sequential-peg-ifn-for-hbv-after-ending-rna-targeted-regimens-100587045","NCT06923280","Sequential PEG-IFN for HBV After Ending RNA-targeted Regimens","Efficacy and Safety of Pegylated Interferon Therapy in Chronic Hepatitis B Patients After Discontinuation of Antisense Oligonucleotide or Small Interfering RNA: A Prospective, Adaptive, Open-label, Randomized Controlled Study","Inclusion Criteria:\n\n* Age ≥18 years.\n* Chronic HBV infection (documented HBsAg positivity for \\>6 months).\n* Prior participation in ASO or siRNA clinical trials:\n* Received ≥1 dose of ASO\u002FsiRNA (or matched placebo, if applicable).\n* Achieved ≥1 log10 IU\u002FmL HBsAg decline from baseline during prior therapy.\n* Discontinued ASO\u002FsiRNA therapy before screening.\n* Screening HBsAg: 1-500 IU\u002FmL.\n* No prior interferon (IFN) therapy within 6 months before enrollment.\n* Willingness to comply with study-related treatments, tests, and procedures.\n* Commitment to contraception during the study.\n* Voluntary participation with signed informed consent.\n\nExclusion Criteria:\n\n* Decompensated cirrhosis or hepatic malignancy (evidenced by imaging or histology within 6 months before\u002Fduring screening).\n* Elevated AFP: Screening AFP \\>100 ng\u002FmL; AFP 20-100 ng\u002FmL with imaging-confirmed hepatocellular carcinoma (ultrasound\u002FCT\u002FMRI).\n* Coinfection with hepatitis A virus (HAV), hepatitis C virus (HCV), hepatitis D virus (HDV), hepatitis E virus (HEV), or human immunodeficiency virus (HIV).\n* Recent immunomodulatory therapy: Systemic corticosteroids, thymosin, or other potent immunomodulators for \\>2 weeks within 6 months before enrollment.\n* Pregnancy, lactation, or plans for pregnancy during the study.\n* Autoimmune hepatitis.\n* Active autoimmune diseases (e.g., psoriasis, systemic lupus erythematosus).\n* Uncontrolled cardiovascular disease (e.g., unstable angina, myocardial infarction within 6 months).\n* Poorly controlled endocrine disorders (e.g., diabetes mellitus, thyroid dysfunction).\n* Severe psychiatric disorders: History of depression, anxiety, bipolar disorder, schizophrenia, or family history of psychiatric conditions (especially depression).\n* Substance abuse: Alcohol (\\>40 g\u002Fday for males; \\>20 g\u002Fday for females) or Illicit drug use.\n* Severe retinopathy or ophthalmologic disorders.\n* Renal diseases: Chronic nephritis, renal insufficiency, nephrotic syndrome.\n* Major organ dysfunction (e.g., heart, lung, pancreas).\n* Organ transplant recipients or candidates.\n* Hypersensitivity to interferon or excipients.\n* Concurrent participation in other HBV-related interventional trials.\n* Other conditions deemed unsuitable by investigators (e.g., non-compliance risk).","80 Years",{"count":134,"type":22},72,[136],"NA","The goal of this clinical trial is to compare sequential PEG-IFNα therapy strategies in chronic hepatitis B (CHB) patients previously treated with ASO\u002FsiRNA. The main questions it aims to answer are:\n\n1. Does sequential PEG-IFNα therapy (vs. deferred\u002Fno treatment) improve HBsAg clearance rates?\n2. What are the HBsAg clearance and relapse rates after 24 weeks of PEG-IFNα therapy?\n3. Is intermittent PEG-IFNα therapy as effective and safe as continuous therapy?\n\nResearchers will compare:\n\n• Group A (immediate 24-week PEG-IFNα + 24-week follow-up) vs. Group B (24-week observation + 24-week PEG-IFNα) in Phase 1 to see if sequential PEG-IFNα therapy will improve HBsAg loss rate .\n\nResearchers will describe:\n\n* The response rate of IFN treatment in non-responders (HBsAg-positive) in Phase 2.\n* The relaspe rate of responders (HBsAg-negative).\n\nParticipants will:\n\nPhase 1 (0-48 weeks):\n\n* Group A: Receive PEG-IFNα for 24 weeks, followed by 24-week treatment-free follow-up.\n* Group B: Undergo 24-week observation, then receive PEG-IFNα for 24 weeks.\n\nPhase 2 (48-96 weeks):\n\n* HBsAg-positive at week 48 patients either from group A or group B : Receive 24-week PEG-IFNα therapy, followed by 24-week follow-up.\n* HBsAg-negative at week 48 patients either from group A or group B: Enter 24-week follow-up without treatment.\n\nAll participants will undergo:\n\n• HBsAg quantification, HBV DNA, liver function, and safety monitoring (every 12 weeks).",[139],"Hepatitis B, Chronic",{"date":141,"type":34},"2026-07-29",{"date":143,"type":34},"2025-08-25",{"date":145,"type":22},"2029-05-31",{"name":40,"class":41},2,{"id":149,"slug":150,"hasResults":12,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":23,"phases":157,"briefSummary":158,"conditions":159,"keywords":161,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":66},"100541419","phase-3-effect-of-ketosteril-on-sarcopenia-in-patients-with-chronic-kidney-disease-100541419","NCT06329622","Effect of Ketosteril on Sarcopenia in Patients With Chronic Kidney Disease","Ketosteril Sarcopenia Chronic Kidney Disease","Inclusion Criteria:\n\n1. Meet the diagnostic criteria for CKD stage 3-4 (15 ≤eGFR\\\u003C60 ml\u002F(min\\*1.73m2)) in the 2012 Kidney Disease Improving Global Outcomes (KDIGO) guideline.\n2. Sarcopenia should be diagnosed According to the 2019 Asian Working Group for Sarcopenia (AWGS) diagnostic criteria for sarcopenia: ① Muscle strength: grip strength (\\\u003C 28 kg for males, \\\u003C 18 kg for females); ② Physical function: is assessed by walking speed over 6 m (\\\u003C 1.0 m\u002Fs) or five-repetition sit-to-stand test (5STS) (≥ 12 s) or recommended short physical performance battery (SPPB) (≤ 9); ③ Artificial skeletal muscle (ASM) of extremities: Bioelectrical impedance analyzer (BIA) (\\\u003C 7.0 kg\u002Fm2 for males and \\\u003C 5.7 kg\u002Fm2 for females). On the basis of meeting criteria ③, sarcopenia can be diagnosed if at least one of the first two items is met.\n3. Patient can walk normally.\n4. Provide the written informed consent.\n\nExclusion Criteria:\n\n1. Patients with diabetes.\n2. Obese\u002Foverweight patients (body mass index\\>25 kg\u002Fm2)\n3. Had previously received renal replacement therapy (including kidney transplantation, hemodialysis, peritoneal dialysis).\n4. Patients with new cardiovascular events, uncontrolled acute or chronic cardiac failure within 3 months.\n5. Patients with acute infection (C-reactive protein\\>10 mg\u002FL) or acute exacerbation of chronic diseases that is not under control within 3 months.\n6. Patients with cerebrovascular events, severe liver disease, malignant tumor and multiple organ failure.\n7. Patients with osteoarthritis, metabolic bone disease, osteonecrosis of the femoral head, hemiplegia and cognitive dysfunction.\n8. Patients with hypercalcemia and amino acid metabolism disorder.\n9. Those who are allergic to the active ingredients or other excipients of the Ketosteril.\n10. Patients with poor compliance, unable to follow the study requirements for diet control.\n11. Participated in other interventional clinical trials within 30 days before this study.",{"count":156,"type":22},58,[26],"The investigators hypothesize that Ketosteril can improve sarcopenia in patients with renal disease without increasing the burden on the kidneys and causing deterioration of renal function. Therefore, this study intends to take patients with CKD stage 3-4 and sarcopenia as the research object, give Ketosteril intervention or not to patients on the base of low-protein diet, and clarify the clinical benefits of Ketosteril prescription for improving sarcopenia in patients with CKD.",[81,160],"Sarcopenia",[110,162],"sarcopenia","2026-07-25",{"date":89,"type":34},{"date":166,"type":34},"2024-05-01",{"date":168,"type":22},"2028-06-30",{"name":40,"class":41},{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":12,"sex":17,"minAge":177,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":181,"conditions":182,"keywords":189,"overallStatus":195,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":4},"100645498","ai-assisted-mri-molecular-subtyping-in-pediatric-brain-tumors-100645498","NCT07703605","AI-Assisted MRI Molecular Subtyping in Pediatric Brain Tumors","AI-Assisted Presurgical MRI Molecular Subtyping for Pediatric Brain Tumors: A Single-Center Ambispective Clinical Cohort Study","Inclusion Criteria:\n\n* Age younger than 18 years at the time of index surgery.\n* Evaluated at a participating study center and scheduled for first surgical treatment of a suspected target pediatric brain tumor.\n* Preoperative brain MRI available before surgery, including at minimum T1-weighted, contrast-enhanced T1-weighted, T2-weighted, and FLAIR sequences in DICOM format; MRI preferably performed within 7 days before surgery and before biopsy or tumor-directed therapy.\n* Postoperative histopathology confirming one of the following target tumor categories: glioma, medulloblastoma, ependymoma, atypical teratoid\u002Frhabdoid tumor, intracranial germ cell tumors, craniopharyngioma, or choroid plexus tumors.\n* For the prospective cohort, written informed consent provided by a parent or legal guardian, with child assent obtained when appropriate according to age, understanding, and local ethics requirements.\n\nExclusion Criteria:\n\n* Postoperative pathology confirming a non-target tumor type.\n* Recurrent tumor, repeat surgery, or prior tumor-directed surgery before the index surgery.\n* Preoperative MRI of inadequate quality for analysis, including severe motion artifact, severe susceptibility\u002Fmetal artifact, or incomplete field of view.\n* Prior biopsy, radiotherapy, chemotherapy, or other tumor-directed treatment before the index preoperative MRI that is judged to substantially affect imaging interpretation.\n* Concurrent malignant disease other than the target brain tumor.\n* Inability to comply with follow-up requirements in the prospective cohort, in the investigator's judgment, because of severe comorbidity or other practical limitations.","0 Years","17 Years",{"count":180,"type":22},1400,"This multicenter observational cohort study aims to develop and validate an artificial intelligence (AI)-assisted diagnostic system for preoperative molecular subtyping of pediatric brain tumors using routine magnetic resonance imaging (MRI). The study will include seven major pediatric brain tumor categories: glioma, medulloblastoma, ependymoma, atypical teratoid\u002Frhabdoid tumor (AT\u002FRT), intracranial germ cell tumors, craniopharyngioma, and choroid plexus tumors.\n\nThe study includes a retrospective cohort for model development and internal\u002Fexternal validation, and a prospective cohort for further validation. Retrospective data will be collected from pediatric patients who underwent first surgical treatment between January 1, 2020 and December 31, 2025. Prospective enrollment will begin on July 15, 2026, with an anticipated sample size of 150 participants. The AI system will analyze preoperative MRI sequences, including T1-weighted, contrast-enhanced T1-weighted, T2-weighted, and FLAIR images, to predict key molecular markers and integrated diagnostic categories. The primary objective is to evaluate the diagnostic performance of the AI system for prespecified molecular prediction tasks using postoperative histopathology and molecular testing as the reference standard. Secondary objectives include assessing agreement with integrated diagnosis, comparing performance against blinded radiologists, and exploring prognostic associations of AI-predicted subgroups.",[183,184,185,186,187,188],"Pediatric Brain Tumors","Glioma","Medulloblastoma","Ependymoma","Craniopharyngioma","Choroid Plexus Tumors",[190,191,192,193,194],"Artificial Intelligence","Molecular Subtyping","Diagnostic Performance","Deep Learning","Pediatric Neuro-Oncology","NOT_YET_RECRUITING","2026-07-21",{"date":198,"type":34},"2026-07-23",{"date":200,"type":22},"2026-07-15",{"date":202,"type":22},"2029-12-30",{"name":40,"class":41},{"id":205,"slug":206,"hasResults":12,"nctId":207,"briefTitle":208,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":210,"enrollmentInfo":211,"targetDuration":213,"studyType":54,"phases":4,"briefSummary":214,"conditions":215,"keywords":219,"overallStatus":195,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":66},"100647556","a-cohort-study-on-the-integrated-management-of-chronic-kidney-disease-100647556","NCT07712341","A Cohort Study on the Integrated Management of Chronic Kidney Disease","Inclusion Criteria:\n\nProspective:\n\n* Patients who have documented outpatient or inpatient records at Huashan Hospital, Shanghai Fifth People's Hospital, or Jing'an District Central Hospital during the period from September 2018 to September 2025.\n* Aged 18-90 years.\n* Diagnosed with one or more of the 48 pre-specified common chronic diseases according to ICD-10 codes.\n* Patients diagnosed with end-stage renal disease (CKD stage 5) and receiving long-term maintenance hemodialysis, with a dialysis vintage of at least 3 months.\n* Have relatively complete hemodialysis records available at the participating center.\n\nRetrospective:\n\n* Patients who meet the diagnostic criteria for chronic kidney disease (CKD) stages 1-5 (non-dialysis) as defined by the KDIGO guidelines, with a disease duration of at least 3 months.\n* Aged 18-80 years, with normal cognitive ability to independently, or with the assistance of a caregiver, complete dietary diaries and quantitative assessments, and willing to provide written informed consent voluntarily.\n* Able to comply with regular outpatient follow-up visits and willing to record a 3-day dietary diary (including both weekdays and weekends) as required.\n\nExclusion Criteria:\n\nProspective:\n\n* Patients whose dialysis-related data and key clinical variables (e.g., creatinine, proteinuria, and other outcome-related indicators) are missing or severely illogical, and which are deemed unusable for research purposes upon evaluation.\n* Patients with poor compliance during dialysis, or those receiving palliative dialysis.\n* Other conditions that the investigators consider inappropriate.\n\nRetrospective:\n\n* Patients who have experienced acute kidney injury within 3 months prior to enrollment, or who are in an acute stress state such as acute infection, myocardial infarction, or other acute conditions at the time of screening.\n* Patients with severe cognitive impairment, mental illness, or insurmountable communication barriers that prevent accurate provision of metabolic assessment information.\n* Pregnant or lactating women; patients currently participating in other drug interventional clinical trials that may interfere with the outcome assessment of this study.","90 Years",{"count":212,"type":22},4029,"2 Years","The study will leverage the established multi-stage cohort resources at Huashan Hospital, covering the entire spectrum from early-stage CKD to dialysis, including a comorbidity real-world database, a prospective CKD patient cohort, and a maintenance hemodialysis patient real-world cohort. It will also collaborate with the Shanghai Fifth People's Hospital (community-based CKD cohort, n\\>2,000) and the Jing'an District Central Hospital (end-stage renal disease cohort, n\\>400) as external validation platforms. Using epidemiological and big data-driven approaches, the study aims to elucidate the mechanisms underlying disease progression and complications, construct intelligent intervention models, and validate their performance in the external cohorts, ultimately facilitating the optimization and broader application of comprehensive CKD management strategies.",[216,217,218],"Chronic Kidney Disease, Stage 5","Chronic Kidney Disease, Stage 4","Chronic Kidney Disease, Stage 3",[81,220],"dialysis","2026-07-14",{"date":223,"type":34},"2026-07-17",{"date":225,"type":22},"2026-09-01",{"date":227,"type":22},"2028-08-30",{"name":40,"class":41},{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":12,"sex":17,"minAge":236,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":23,"phases":239,"briefSummary":240,"conditions":241,"keywords":244,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":253,"locationsCount":254},"100517792","phase-3-a-novel-therapy-with-a-1-month-ultrashort-regimen-to-halt-progression-from-latent-infection-to-active-tuberculosis-among-close-contacts-the-tb-youth-study-100517792","NCT06022146","A Novel Therapy With a 1-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB-YOUTH Study)","TB-YOUTH","Inclusion Criteria:\n\n1. Aged ≥13 years and body weight ≥ 30 kg;\n2. School-registered individuals including:\n\n   * Currently attending junior \u002F senior high school or university students;\n   * School staff members;\n3. Close contacts of active pulmonary TB index cases (confirmed or clinically diagnosed) within the school, defined by meeting both of the following:\n\n   * Teachers\u002Fstudents sharing the same classroom or dormitory with the index case;\n   * Exposure history: Prolonged sharing of enclosed space (\\>4 hours total within 1 week) with the index case;\n4. Confirmed LTBI status through screening;\n5. Voluntary participation with signed informed consent form (for adults ≥18 years);\n6. Parental \u002F guardian consent and co-signed informed consent form (for minors aged 13-17 years).\n\nExclusion Criteria:\n\n1. Current active TB disease (clinically or bacteriologically confirmed);\n2. Documented isoniazid\u002Frifampicin resistance in the corresponding M. tuberculosis strain from the index case;\n3. Self-reported use of rifamycins (e.g., rifampicin, rifapentine) or isoniazid for \\>14 consecutive days within the past 2 years;\n4. Prior completion of full-course of treatment for ATB or LTBI;\n5. Hypersensitivity or intolerance to rifamycins (rifapentine \u002F rifampicin) or isoniazid;\n6. HIV positive serostatus or AIDS patients;\n7. History of viral hepatitis (e.g., chronic hepatitis B, chronic hepatitis C) or liver cirrhosis;\n8. Liver dysfunction (TBil\\>2.5mg\u002FdL \\[43umol\u002FL\\] or ALT \u002F AST\\>2ULN) or renal dysfunction.\n9. Current receiving immunosuppressive therapy or biological agents.\n10. Hematologic disorders with either PLT\\\u003C50×109\u002FL or WBC\\\u003C3.0×109\u002FL.\n11. Other conditions deemed unsuitable for TPT by investigators.","13 Years",{"count":238,"type":22},3520,[26],"This is a prospective, multi-center, open-label, cluster randomized controlled clinical trial conducted in school settings to estimate the non-inferiority effect of 1H3P3 compared with 3HR.",[242,243],"Tuberculosis","Latent Tuberculosis",[245,246,247],"latent tuberculosis","TPT","active screening","2026-07-13",{"date":221,"type":34},{"date":251,"type":34},"2023-09-01",{"date":225,"type":22},{"name":40,"class":41},66,{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":23,"phases":263,"briefSummary":265,"conditions":266,"keywords":269,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":66},"100647482","early-phase-1-a-study-to-evaluate-the-human-biodistribution-and-dosimetry-of-the-radionuclide-labeled-ir199-in-patients-with-gastric-cancer-and-pancreatic-cancer-100647482","NCT07707531","A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer","Inclusion Criteria:\n\n1. Informed consent must be obtained in writing from the subject, their legally authorized representative, or caregiver.\n2. Age equal to or above 18 years old.\n3. Histologically or cytologically confirmed gastric cancer or pancreatic cancer with Claudin 18.2 expression.\n4. Must have ≥1 Claudin 18.2 positive lesions.\n\nExclusion Criteria:\n\n1. Less than two weeks since the last treatment that could cause bone marrow suppression.\n2. Known or suspected history of ≥3 grade renal and urinary system diseases.\n3. Medical history of allergy, hypersensitivity reaction or intolerance to radioactive drugs.",{"count":262,"type":22},10,[264],"EARLY_PHASE1","This study is to evaluate the safety, biodistribution, radiation dosimetry and tumor uptake of the \\[68Ga\\]\u002F \\[131I\\]-IR199 in patients with Claudin 18.2 positive gastric cancer and pancreatic cancer.",[267,268],"Gastric Cancer","Pancreatic Cancer",[270,271],"gastric cancer","pancreatic cancer","2026-07-11",{"date":274,"type":34},"2026-07-16",{"date":276,"type":34},"2026-06-01",{"date":278,"type":22},"2027-05-31",{"name":40,"class":41},{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":132,"enrollmentInfo":287,"targetDuration":4,"studyType":23,"phases":289,"briefSummary":290,"conditions":291,"keywords":4,"overallStatus":195,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":66},"100646431","phase-2-safety-and-efficacy-of-edaravone-dexborneol-sublingual-tablets-for-blood-brain-barrier-dysfunction-in-cadasil-100646431","NCT07692399","Safety and Efficacy of Edaravone Dexborneol Sublingual Tablets for Blood-Brain Barrier Dysfunction in CADASIL","Safety and Efficacy of Edaravone Dexborneol Sublingual Tablets for Blood-Brain Barrier Dysfunction in CADASIL: A Single-Center, Prospective, Single-Arm, Self-Controlled Clinical Trial.","Inclusion Criteria:\n\n* 1\\. Genetically Confirmed CADASIL: Diagnosis of CADASIL confirmed by NOTCH3 genetic testing.\n* 2\\. Age: Between 18 and 80 years.\n* 3\\. Lacunar Lesion Requirement: Presence of ≥1 lacune on brain MRI.\n* 4\\. No acute ischemic stroke or intracerebral hemorrhage within the past 3 months.\n* 5\\. Modified Rankin Scale (mRS) score of 0 to 3.\n* 6\\. Contraception Requirements: Women of childbearing potential and male participants with female partners of childbearing potential must agree to use effective contraception during the study and 30 days after the last dose of the investigational drug.Female participants must have a negative pregnancy test before enrollment.\n* 7\\. Informed Consent: Participants or their legal representatives must voluntarily sign an informed consent form (ICF).\n\nExclusion Criteria:\n\n* 1\\. Presence of other major neurological disorders: Non-vascular white matter diseases (e.g., multiple sclerosis, carbon monoxide encephalopathy), central nervous system infections, Creutzfeldt-Jakob disease, primary Parkinson's disease, traumatic brain injury, or intracranial tumors.\n* 2\\. Severe Liver Dysfunction: Active liver disease (acute hepatitis, chronic active hepatitis, cirrhosis) or ALT\u002FAST \\>2× ULN.\n* 3\\. Severe renal impairment (serum creatinine \\>1.5× ULN).\n* 4\\. Life Expectancy \\\u003C1 year due to severe systemic diseases.\n* 5\\. Contraindications to MRI: Participants with MRI-incompatible implants, severe claustrophobia, or inability to undergo MRI.\n* 6\\. Known Allergies: History of hypersensitivity to Dexborneol, natural borneol, edaravone, or any excipients (e.g., mannitol, copovidone, microcrystalline cellulose, silica, magnesium stearate).\n* 7\\. Pregnancy and Lactation: Pregnant or lactating women, or those planning pregnancy during the study period.\n* 8\\. Participation in Other Clinical Trials\n* 9\\. Other Investigator-Determined Factors: Any other medical, psychological, or social condition that, in the investigator's judgment, makes the patient unsuitable for participation.",{"count":288,"type":22},60,[25],"This study is a single-center, prospective, single-arm, self-controlled clinical trial designed to assess the safety and efficacy of edaravone dexborneol sublingual tablets for blood-brain barrier (BBB) dysfunction in patients with CADASIL.\n\nThe study will enroll approximately 60 participants aged 18 to 80 years with genetically confirmed CADASIL. Participants will be followed for a total duration of 12 months, including two consecutive phases.\n\n* Phase 1 is a 6-month natural history observation period, during which participants do not receive the study drug and continue their routine standard care for CADASIL.\n* Phase 2 is a 6-month drug intervention period, in which participants will receive edaravone dexborneol sublingual tablets to investigate the effect on the BBB water exchange rate (kw), measured by diffusion-prepared pseudo-continuous arterial spin labeling (DP-pCASL) MRI, and to assess potential benefits on stroke risk reduction, cognitive function, and gait performance.\n\nThe primary endpoint is the change in kw measured by DP-pCASL. Secondary endpoints include the incidence of clinical stroke events; changes in neuropsychological performance, MRI-based CSVD biomarkers, gait and motor assessments, functional disability and activities-of-daily-living scales, and peripheral blood biomarkers. Safety assessments will include adverse events (AEs) and serious adverse events (SAEs).",[292],"CADASIL","2026-07-03",{"date":295,"type":34},"2026-07-09",{"date":297,"type":22},"2026-07",{"date":299,"type":22},"2027-12",{"name":40,"class":41},{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":310,"conditions":311,"keywords":315,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":331},"100646033","clinical-multimodal-surveillance-of-respiratory-syndrome-pathogens-100646033","NCT07694648","Clinical Multimodal Surveillance of Respiratory Syndrome Pathogens","Clinical Multimodal Early Warning Surveillance of Respiratory Syndrome Pathogens and Construction and Application of Prevention and Control Measures","Inclusion Criteria:\n\n* Patients with respiratory syndrome: Eligible patients are those diagnosed with respiratory syndrome based on the predefined data dictionary and the following ICD-10 (International Statistical Classification of Diseases, 10th Revision) diagnosis codes: R05, R50, J00, J01, J02, J03, J04, J06, J07, J08, J09, J10, J11, J12, J13, J14, J15, J16, J17, J18, J20, J21, J98.414, and J98.802.\n* Patients with respiratory syndrome: Eligible patients are identified using the following search criteria. Patients meeting any one of the following criteria should be included:\n\n  1. Medical history (History of Present Illness): Positive test result for a respiratory syndrome-related pathogen.\n  2. Laboratory testing: Positive test result for a respiratory syndrome-related pathogen.\n  3. Medication: Receipt of any of the following antiviral agents:\n\n     Nirmatrelvir\u002FRitonavir Leritrelvir Xiannuotewei\u002FRitonavir Molnupiravir Azvudine Deuremidevir\n  4. Diagnosis: Diagnosis containing the term \"respiratory tract infection.\"\n\nExclusion Criteria:\n\n* Participants who may compromise the study results: Patients who are unable to provide a specimen or whose specimen volume is insufficient for laboratory testing.\n* Participants who are unable to comply with study procedures.",{"count":309,"type":22},2398,"This nationwide, multicenter observational study will establish and improve a hospital-based clinical surveillance and early warning system for respiratory syndrome pathogens. Clinical data and biospecimens generated during routine care will be collected from participating medical institutions every two weeks to monitor pathogen trends, support risk assessment, and provide evidence for prevention and control measures.",[312,313,314],"Respiratory Tract Infections (RTI)","Respiratory Syndrome, Acute, Severe","Acute Respiratory Infections (ARIs)",[316,317,318,319,320,321,322,323],"Respiratory syndrome","respiratory pathogens","clinical surveillance","early warning","multiplex PCR","metagenomic next-generation sequencing","multi-omics","nationwide multicenter study",{"date":325,"type":34},"2026-07-10",{"date":327,"type":34},"2025-09-01",{"date":329,"type":22},"2028-09-30",{"name":40,"class":41},31,{"id":333,"slug":334,"hasResults":12,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":17,"minAge":340,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":343,"conditions":344,"keywords":347,"overallStatus":195,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":359,"locationsCount":4},"100646880","development-and-validation-of-an-ai-foundation-model-for-cns-tumor-classification-100646880","NCT07685301","Development and Validation of an AI Foundation Model for CNS Tumor Classification","Development and Validation of an Artificial Intelligence Foundation Model for Hierarchical Classification of Central Nervous System Tumors Using Hematoxylin and Eosin Whole-Slide Images","CNS-AIClass","Inclusion Criteria:\n\n1. Patients who underwent brain or spinal tumor resection or biopsy at Huashan Hospital Fudan University and Shandong Provincial Hospital.\n2. Postoperative pathology diagnosis consistent with a primary or secondary central nervous system tumor.\n3. Availability of archived routine H\\&E-stained glass slides or existing digital whole-slide image files of adequate quality for analysis.\n4. Availability of essential de-identified clinical and pathological information, including age, sex, tumor location, and key surgical\u002Fpathology records.\n5. Use of archived data and samples permitted under institutional ethics approval, including waiver of informed consent where applicable.\n\nExclusion Criteria:\n\n1. Severe slide preparation or scanning artifacts that preclude meaningful computational analysis, including extensive tissue folding, severe bubbles, severe detachment, markedly uneven staining\u002Ffading, or severe out-of-focus scanning.\n2. Insufficient viable tumor tissue or insufficient analyzable tumor area for patch extraction.\n3. Missing or uncertain pathological diagnosis that cannot be reliably reassigned according to the WHO 2021 CNS tumor classification using available records.\n4. Cases lacking sufficient clinical, pathological, or molecular information required for core study analyses.\n5. Other cases determined by the investigators to be unsuitable for algorithm training or evaluation after quality control review.","9 Years",{"count":342,"type":22},20000,"This is a multi-center, retrospective, observational study to develop and internally validate an artificial intelligence (AI) foundation model for hierarchical classification of central nervous system (CNS) tumors using approximately 20,000 hematoxylin and eosin (H\\&E) whole-slide images (WSIs) collected at Huashan Hospital Fudan University and Shandong Provincial Hospital. Archived pathology slides and linked de-identified clinical, histopathological, and molecular diagnostic data from patients who underwent neurosurgical tumor resection or biopsy between January 1, 2010 and December 31, 2025 will be retrospectively analyzed.\n\nThe study aims to train and evaluate weakly supervised multiple-instance learning models using pathology foundation models and conventional convolutional neural network feature extractors to predict tumor category, tumor family, terminal WHO 2021 CNS tumor diagnosis, and selected molecular alterations directly from routine H\\&E slides. Internal model validation will be performed using patient-level training, validation, and hold-out test datasets. Secondary analyses include comparison of model architectures, virtual molecular profiling, interpretability analyses using attention heatmaps, and comparison of AI-assisted versus pathologist-only diagnostic performance on selected internal test cases.",[345,346],"Brain Tumors","Central Nervous System Neoplasms",[190,348,349,350,351,352],"Brain Tumor","CNS Tumor","Whole-Slide Imaging","Computational Pathology","Digital Pathology","2026-06-29",{"date":355,"type":34},"2026-07-06",{"date":357,"type":22},"2026-08-01",{"date":38,"type":22},{"name":40,"class":41},{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":364,"acronym":4,"eligibilityCriteria":365,"healthyVolunteers":49,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":195,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":378,"locationsCount":4},"100643096","research-project-on-the-interaction-between-immune-function-and-infectious-diseases-in-older-adults-and-the-development-of-prevention-and-control-strategies-100643096","NCT07644962","Research Project on the Interaction Between Immune Function and Infectious Diseases in Older Adults and the Development of Prevention and Control Strategies","Inclusion Criteria:\n\n\\- General Cohort Inclusion Criteria\n\n1. Adults aged 60 years or older who are in generally good health, defined as having no severe organ dysfunction that significantly affects daily living activities (e.g., decompensated heart, liver, or kidney failure), adequate nutritional status (without significant wasting or malnutrition), and the ability to communicate and comply with study procedures.\n2. Male or female.\n3. Able to understand the study and voluntarily provide written informed consent.\n\nInfection Cohort Inclusion Criteria\n\n1. Adults aged 60 years or older, regardless of sex.\n2. Patients with an infectious disease diagnosed by a qualified clinician.\n\nExclusion Criteria:\n\n* General Cohort Exclusion Criteria\n\n  1. Refusal to participate in this study.\n  2. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for enrollment.\n\nInfection Cohort Exclusion Criteria\n\n1. Final primary diagnosis is a non-infectious disease (e.g., connective tissue disease, malignancy, or other non-infectious conditions).\n2. Positive culture results determined by the treating clinician to represent colonization or contamination rather than true infection.\n3. Refusal to participate in this study.\n4. Critically ill patients or those unable to cooperate with specimen collection procedures.\n5. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for enrollment.",{"count":367,"type":22},23000,"As population aging accelerates, infectious diseases have become a major factor affecting the health, quality of life, and survival outcomes of older adults. Immunosenescence, chronic low-grade inflammation (inflammaging), and dysbiosis of the respiratory and gut microbiota are considered important mechanisms underlying increased susceptibility to infection and a higher risk of severe disease in older adults. However, the interactions among these factors and their impact on infection-related outcomes remain incompletely understood.\n\nBuilding upon a previously established pilot cohort of older adults, this study aims to further identify and validate key biological characteristics and risk factors associated with infectious diseases through large-scale population follow-up. A large prospective cohort of older adults will be established, while retrospective healthcare data collected since 2019 will also be integrated. Demographic information, comorbidities, medication history, infection-related clinical data, and biological specimens, including blood, urine, fecal, and respiratory samples, will be collected for long-term longitudinal follow-up. By integrating immunological assessments, immune repertoire analyses, microbiome profiling, and other multi-omics technologies, this study will systematically evaluate the effects of immunosenescence, respiratory and gut microbiome alterations, and environmental and climatic factors on the occurrence, severity, and prognosis of infectious diseases in older adults. The study aims to identify key biomarkers and microbial signatures associated with infection risk and to develop risk prediction and early warning models for infectious diseases in older adults, thereby providing scientific evidence for precision prevention, optimized clinical management, and public health decision-making in aging populations.",[370,57,371],"Infectious Diseases","Aging","2026-06-08",{"date":374,"type":34},"2026-06-12",{"date":376,"type":22},"2026-06-09",{"date":202,"type":22},{"name":40,"class":41},{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":4,"eligibilityCriteria":385,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":23,"phases":388,"briefSummary":389,"conditions":390,"keywords":4,"overallStatus":195,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":397,"locationsCount":66},"100643786","phase-2-vertebrobasilar-dolichoectasia-treatment-with-amiloride-100643786","NCT07634068","Vertebrobasilar Dolichoectasia Treatment With Amiloride","Vertebrobasilar Dolichoectasia Treatment With Amiloride: a Pilot Study Based On 5.0 T MRI","Inclusion Criteria:\n\n1. Age≥18 years, any gender;\n2. Patients with VBD confirmed by DSA\u002FCTA\u002FMRA;\n3. No history of VBD rupture and no surgical treatment for VBD;\n4. mRS\\\u003C4;\n5. Positive plasma SGK1;\n6. No history of posterior circulation stroke, and no symptoms or signs related to VBD;\n7. No need for subsequent use of antiplatelet or statin drugs;\n8. Capable of signing an informed consent form with the accompaniment and understanding of a guardian.\n\nExclusion Criteria:\n\n1. History of malignant tumors, systemic lupus erythematosus, or gout;\n2. Pregnancy or lactation;\n3. Amiloride or sulfonamide allergy;\n4. Hydrocephalus requiring urgent surgical intervention or respiratory failure requiring life support treatment;\n5. Abnormal hepatic and\u002For renal function (serum transaminase \\> 40 U\u002FL; serum creatinine \\> 110 μmol\u002FL); and\u002For abnormal white blood cells\u002Fplatelets (white blood cells count \\\u003C 3.5 × 10⁹\u002FL or \\> 9.5 × 10⁹\u002FL; platelets count \\\u003C 100 × 10⁹\u002FL or \\> 300 × 10⁹\u002FL); hyperkalemia, hypokalemia, hyponatremia, or hypercalcemia;\n6. Acute cerebral infarction within the last month or definite high signal on DWI indicating acute or subacute cerebral infarction;\n7. Acute stage of intracranial hemorrhage as indicated by CT;\n8. History of VBD rupture or surgery;\n9. Presence of acute active infection (such as severe bacterial, viral or fungal infection);\n10. Uncontrolled diabetes (HbA1c≥7%);\n11. Need for subsequent use of antiplatelet or statin drugs;\n12. Systolic blood pressure\\\u003C 90 mmHg or\u002Fand diastolic blood pressure\\\u003C 60 mmHg;\n13. Currently participating in other clinical studies;\n14. Presence of contraindications for MRI examination;\n15. Other situations not suitable for inclusion.",{"count":387,"type":22},6,[25],"The aim of this pilot study is to assess the efficacy of amiloride in reducing wall enhancement in vertebrobasilar dolichoectasia(VBD) on high-resolution magnetic resonance vessel wall imaging(HR-VWI) via anti-inflammatory mechanisms, clarify the efficacy of amiloride in delaying the progression of VBD, evaluate the safety of amiloride in the treatment of VBD.",[391],"Vertebrobasilar Dolichoectasia","2026-06-03",{"date":372,"type":34},{"date":395,"type":22},"2026-06",{"date":299,"type":22},{"name":40,"class":41},{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":23,"phases":407,"briefSummary":408,"conditions":409,"keywords":4,"overallStatus":195,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":410,"startDateStruct":411,"completionDateStruct":412,"leadSponsor":413,"locationsCount":66},"100643320","phase-2-vertebrobasilar-dolichoectasia-treatment-with-sirolimus-100643320","NCT07634120","Vertebrobasilar Dolichoectasia Treatment With Sirolimus","Vertebrobasilar Dolichoectasia Treatment With Sirolimus: a Pilot Trial Based On 5.0 T MRI","Inclusion Criteria:\n\n1. Age≥18 years, any gender;\n2. Patients with VBD confirmed by DSA\u002FCTA\u002FMRA;\n3. No history of VBD rupture and no surgical treatment for VBD;\n4. mRS\\\u003C4;\n5. Positive plasma SGK1;\n6. History of posterior circulation infarction or accompanied by VBD-related symptoms\u002Fsigns;\n7. Currently and in the future, need to take antiplatelet and statin drugs simultaneously, or currently and in the future, do not need to take antiplatelet and statin drugs;\n8. Capable of signing an informed consent form with the accompaniment and understanding of a guardian.\n\nExclusion Criteria:\n\n1. History of malignant tumors;\n2. Pregnancy or lactation;\n3. Sirolimus allergy;\n4. Hydrocephalus requiring urgent surgical intervention or respiratory failure requiring life support treatment;\n5. Abnormal hepatic and\u002For renal function (serum transaminase \\> 40 U\u002FL; serum creatinine \\> 110 μmol\u002FL); and\u002For abnormal white blood cells\u002Fplatelets (white blood cells count \\\u003C 3.5 × 10⁹\u002FL or \\> 9.5 × 10⁹\u002FL; platelets count \\\u003C 100 × 10⁹\u002FL or \\> 300 × 10⁹\u002FL);\n6. History of immunosuppressive therapy;\n7. Acute cerebral infarction within the last month or definite high signal on DWI indicating acute or subacute cerebral infarction;\n8. Acute stage of intracranial hemorrhage as indicated by CT;\n9. History of VBD rupture or surgery;\n10. Presence of acute active infection (such as severe bacterial, viral or fungal infection);\n11. Uncontrolled diabetes (HbA1c≥7%);\n12. History of liver or lung transplantation;\n13. Presence of organic heart disease;\n14. History of arteriovenous thrombosis;\n15. Patients taking only antiplatelet drugs or only statin drugs;\n16. Patients taking or needing to take CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, clarithromycin, erythromycin, telithromycin, ritonavir, atazanavir, diltiazem, verapamil, cyclosporine, amiodarone, sildenafil, grapefruit juice, etc.) or CYP3A4 inducers (rifampicin, rifabutin, phenobarbital, phenytoin, carbamazepine, dexamethasone, St. John's wort, etc.);\n17. Currently participating in other clinical studies;\n18. Presence of contraindications for MRI examination;\n19. Other situations not suitable for inclusion.",{"count":406,"type":22},12,[25],"The aim of this pilot trial is to assess the efficacy of sirolimus in reducing wall enhancement in vertebrobasilar dolichoectasia(VBD) on 5 T high-resolution magnetic resonance vessel wall imaging(HR-VWI) via anti-inflammatory mechanisms, clarify the efficacy of sirolimus in delaying the progression of VBD, evaluate the safety of sirolimus in the treatment of VBD.",[391],{"date":372,"type":34},{"date":395,"type":22},{"date":299,"type":22},{"name":40,"class":41},{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":420,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":422,"conditions":423,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":434},"100636864","identification-and-molecular-characterisation-of-urban-environmental-stress-patterns-affecting-mental-illness-100636864","NCT07571226","Identification and Molecular Characterisation of Urban-environmental Stress Patterns Affecting Mental Illness","Inclusion Criteria:\n\n1. Diagnosis: The primary diagnosis meets the DSM-IV criteria for depressive disorder, generalized anxiety disorder, or alcohol use disorder, and comorbid conditions may be present;\n2. Patients with mental disorders aged 18-60 years, with a balanced gender ratio;\n3. Normal intelligence and ability to use a smartphone running the Android operating system;\n4. Willingness to wear a wristband equipped with physiological monitoring functions (such as heart rate and electrodermal activity), download the study application, and upload data during the study period;\n5. Participants with depression or generalized anxiety disorder who are taking medication must be on a single stable dose of a selective serotonin reuptake inhibitor (SSRI), specifically citalopram or escitalopram, and this medication regimen must have been maintained for at least 5 days. Participants with alcohol use disorder who are taking medication have no restriction on the type of drug, but the medication regimen should also have been maintained for at least 5 days. At baseline assessment, patients with depression or anxiety disorders should have a Hamilton Depression Rating Scale (HAMD-17) score \\>7 or a Hamilton Anxiety Rating Scale (HAMA-14) score \\>7.;\n6. Voluntary participation in this study and signing of informed consent;\n7. For patients with alcohol use disorder (AUD): AUD patients must have successfully completed alcohol withdrawal, confirmed by clinical standards or relevant healthcare professionals.\n\nInclusion Criteria for Healthy Control Group\n\n1. Healthy subjects aged 18-60 years, with a balanced gender ratio;\n2. Normal intelligence and ability to use a smartphone running the Android operating system;\n3. Willingness to wear a wristband equipped with physiological monitoring functions (such as heart rate and electrodermal activity), download the study application, and upload data during the study period;\n4. Voluntary participation in this study and signing of informed consent.\n\nExclusion Criteria:\n\n1. Currently taking opioid medications;\n2. Receiving any form of brain stimulation therapy within the past 1 month (including transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), or other similar treatments);\n3. Skin infection or severe skin damage on the wrist or upper limbs that may affect the normal use of monitoring devices;\n4. Recent use (within 30 days) of medications that may interfere with drug metabolism, such as strong CYP450 inhibitors\u002Finducers;\n5. Severe physical diseases (such as brain tumors or injuries) or special conditions (such as current pregnancy or lactation) that may affect the study protocol;\n6. HAMD-17 item 3 (suicide) \\>3 points (severe suicidal behavior);\n\nExclusion Criteria for Healthy Control Group\n\n1. Currently using benzodiazepines or opioid medications;\n2. Currently receiving any form of brain stimulation therapy (including transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), or other similar treatments);\n3. Skin infection or severe skin damage on the wrist or upper limbs that may affect the normal use of monitoring devices;\n4. Recent use (within 30 days) of medications that may interfere with drug metabolism, such as strong CYP450 inhibitors\u002Finducers, or not reaching steady-state drug concentration before the study;\n5. Severe physical diseases (such as brain tumors or injuries) or special conditions (such as current pregnancy or lactation) that may affect the study protocol.",{"count":421,"type":22},680,"Mental disorders have become a major contributor to the global burden of non-communicable diseases, with disability-adjusted life years (DALYs) attributable to these conditions continuing to rise. Although evidence suggests that environmental factors may account for up to 40% of the attributable risk for mental disorders such as major depressive disorder, anxiety disorders, and alcohol use disorder, the underlying mechanisms remain unclear, particularly regarding how dynamic environmental stress influences disease onset, progression, and relapse. Traditional research has primarily focused on individual-level psychosocial factors, including socioeconomic status and life events, while lacking real-time, multidimensional assessments of objective urban environmental stressors such as air pollution, noise exposure, and reduced green space.\n\nThis study proposes a prospective longitudinal cohort design based in real-world environments, enrolling both patients with mental disorders and healthy controls. Using wearable devices integrated with the \"'StreetMind'\" mobile application and wear the visible watch, we will continuously and dynamically collect multimodal data on environmental exposures and physiological responses in urban settings. These include photoplethysmography (PPG)-derived heart rate, oxygen saturation, physical activity, and gait parameters, as well as objective environmental indicators such as temperature, humidity, light intensity, and noise levels. At baseline, all participants will undergo standardized psychiatric assessments to characterize depressive, anxiety, and addictive conditions. Peripheral blood and urine samples will also be collected for subsequent molecular and multi-omics analyses.\n\nThe study aims to systematically evaluate the associations between urban environmental factors-including air pollution, noise exposure, and green space availability-and the risk of mental disorder relapse. Furthermore, it seeks to elucidate the potential mechanisms by which environmental stress affects mental health through neuroinflammation and alterations in brain circuitry. The findings are expected to provide novel insights for risk prediction, early intervention, and precision management of mental disorders.",[424,425,426],"Major Depressive Disorder (MDD)","Anxiety Disorder","Alcohol Use Disorder (AUD)","2026-05-31",{"date":392,"type":34},{"date":430,"type":34},"2026-04-10",{"date":432,"type":22},"2029-05-30",{"name":40,"class":41},3,{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":49,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":441,"targetDuration":442,"studyType":54,"phases":4,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":195,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":4},"100640317","multi-center-validation-study-of-a-large-language-model-based-intelligent-agent-for-blood-cell-analysis-100640317","NCT07607184","Multi-center Validation Study of a Large Language Model-based Intelligent Agent for Blood Cell Analysis","Inclusion Criteria:\n\n* Subjects who underwent routine blood tests in the outpatient, emergency, or inpatient departments of the participating centers during the study period.\n\nCorresponding samples must have complete instrument results, review trails, and report timestamp records.\n\nApproved for inclusion by the Ethics Committee.\n\nExclusion Criteria:\n\n* Samples collected during periods of instrument malfunction or interface transmission anomalies.\n\nMissing key research data, particularly samples where the final review conclusion or key timestamps cannot be confirmed.\n\nSubjects or their legal representatives explicitly refuse to participate in the study.",{"count":342,"type":22},"1 Year","I. Study Background: Currently, in most medical institutions, the review of blood cell analysis still heavily relies on manual verification by laboratory staff. This process requires a comprehensive analysis of instrument parameters, alarm flags, historical comparison results, and, when necessary, microscopic examination. However, with the increasing volume of test samples and the high concentration of review tasks during peak hours, the traditional manual review model increasingly shows problems such as prolonged turnaround time (TAT), uneven workload distribution, and decreased consistency in reviews. In recent years, intelligent review systems based on Large Language Models (LLM) have shown potential in analyzing abnormal results and stratifying sample risks by integrating preset rules, clinical diagnostic information, and multi-dimensional laboratory data, which is expected to optimize the review workflow.\n\nII. Study Objective: To evaluate the difference in overall sample review turnaround time between the experimental process and the control process during the formal study phase, and to test its superiority.\n\nIII. Subjects: The investigators need to recruit approximately 20,000 subjects, regardless of age or gender.\n\nIV. Study Procedures: If participants agree to participate in the study, participants only need to allow us to use participants test results after participants have completed your routine blood test (CBC).\n\nV. Risks and Benefits:\n\n1. Risks: This study poses no risk to the subjects. The investigators only use the result data of patients after participants have had their routine blood test; there is no need for patients to undergo additional blood draws.\n2. Benefits: It will shorten the turnaround time for routine blood test results and share the workload of doctors in reviewing these results.\n\nVI. Privacy: All of participants information will be kept strictly confidential and will only be used for this scientific research.",[445],"Complete Blood Count Review","2026-05-24",{"date":448,"type":34},"2026-05-28",{"date":450,"type":22},"2026-05-14",{"date":452,"type":22},"2027-08-31",{"name":40,"class":41},{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":463,"conditions":464,"keywords":468,"overallStatus":195,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":475,"completionDateStruct":476,"leadSponsor":477,"locationsCount":147},"100640904","artificial-intelligence-driven-tuberculosis-landscape-analysis--stratification-research-100640904","NCT07611695","Artificial Intelligence-driven Tuberculosis Landscape Analysis & Stratification Research","TB-ATLAS","Inclusion Criteria for Model Development Cohort:\n\n* Patient with clinically diagnosed or bacteriologically confirmed pulmonary tuberculosis (TB) who received TB treatment;\n* Initiation of TB treatment on or after January 1, 2021;\n* Complete key diagnosis and treatment data available in the electronic medical record system.\n\nInclusion Criteria for External Validation Cohort:\n\n* Patient with clinically diagnosed or bacteriologically confirmed pulmonary tuberculosis (TB) who is planning to start TB treatment;\n* Voluntary participation with signed informed consent form (for adults ≥18 years); parental \u002F guardian consent and co-signed informed consent form are required for minors aged ≤ 18 years.\n\nExclusion Criteria:\n\n* Co-morbidity confounding: the presence of other active, life-threatening disease (e.g. late-stage malignancy, non-HIV severe immunodeficiency) for which the expected survival or priority of treatment may substantially interfere with the attribution of TB treatment outcomes;\n* Extremely poor treatment adherence: documented evidence indicating that the patient either never initiated treatment or was permanently lost to follow-up within the early treatment period (\\\u003C2 weeks), precluding the collection of any valid outcome data.",{"count":462,"type":22},31600,"The goal of this observational study is to establish and validate a comprehensive AI-driven clinical decision support system (AI-CDSS) in whole-chain management for pulmonary tuberculosis (TB) patients. The main question it aims to answer is:\n\nHow is the predictive performance of this system in terms of multiple key links during TB diagnosis and treatment? Can real-world benefits be derived from this system? This AI framework supports clinicians in making smarter decisions, ultimately improving cure rates and ensuring that every patient receives the most effective, personalized care possible.",[465,466,467],"Pulmonary Tuberculosis","Tuberculosis (TB)","Tuberculosis Active",[469,470,471,472],"tuberculosis","artificial intelligence","predictive model","clinical decision support system","2026-05-20",{"date":448,"type":34},{"date":276,"type":22},{"date":168,"type":22},{"name":40,"class":41},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":23,"phases":487,"briefSummary":488,"conditions":489,"keywords":492,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":66},"100546961","the-effectiveness-and-safety-of-body-posture-in-preventing-postoperative-recurrence-for-chronic-subdural-hematoma-100546961","NCT06401772","The Effectiveness and Safety of Body Posture in Preventing Postoperative Recurrence for Chronic Subdural Hematoma","The Effectiveness and Safety of Body Posture to Improve Intracranial Pressure in Preventing Postoperative Recurrence for Chronic Subdural Hematoma (BP-CSDH) -A Multicenter Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. chronic subdural hematoma is diagnosed with CT\u002FMRI scan; thickness of hematoma is more than 1 cm;\n2. more than 60 years of age or 60 years;\n3. MGS-GCS (Markwalder's Grading Scale and Glasgow Coma Scale) is less than or equal to 2;\n4. patients have neurological symptom caused by CSDH before surgery, such as headache, dizziness, nausea, vomiting, numbness or weakness of limb, instability to walk, unconsciousness, trouble speaking, insensitive, etc.\n5. receive burr hole drainage;\n6. sign informed consent voluntarily.\n\nExclusion Criteria:\n\n1. have brain hernia or acute massive cerebral infarction that have to perform craniotomy\n2. have severe malignancies, hemorrhagic disease, cardiac dysfunction and other serious disease that may impede recovery or follow-up compliance;\n3. Spinal deformities (e.g., kyphosis) or psychiatric disorders precluding prolonged body posture therapy adherence\n4. Concomitant severe intracranial tumors, aneurysms, or vascular malformations that may impede recovery.\n5. Patients with cranial CT demonstrating no significant compression or displacement of brain tissue, asymptomatic presentation, and unaffected daily activities were deemed ineligible for surgical intervention by neurosurgeons;\n6. CSDH persisting for over 1 year and exhibiting marked organization\u002Fsolidification of the hematoma;\n7. CSDH caused by over V-P shunting;\n8. during burr hole drainage, patients have to perform craniotomy due to acute bleeding or brain hernia;\n9. Intraoperative complications (e.g., cerebral contusion, intraparenchymal catheter placement) during burr hole drainage;\n10. have deep venous thrombosis of lower extremity or pulmonary embolism;\n11. cannot complete regular reexamine within 1 year for any reason;\n12. life expectancy less than 1 year;\n13. participating other ongoing clinical trial;\n14. patients are not qualified for other reason evaluated by two neurosurgeons;\n15. have bile reflux gastritis and esophageal diseases.",{"count":486,"type":22},830,[136],"This study aims to investigate the effectiveness and safety of body posture to improve intracranial pressure in preventing postoperative recurrence for chronic subdural hematoma",[490,491],"Chronic Subdural Hematoma","Recurrence",[490,493,494],"body posture","intracranial pressure","2026-04-26",{"date":497,"type":34},"2026-04-30",{"date":499,"type":34},"2024-08-08",{"date":501,"type":22},"2028-01",{"name":40,"class":41},{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":510,"targetDuration":4,"studyType":23,"phases":512,"briefSummary":513,"conditions":514,"keywords":4,"overallStatus":195,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":523,"locationsCount":4},"100635446","impact-of-hand-rub-placement-on-patient-trust-and-disease-stigma-100635446","NCT07552792","Impact of Hand Rub Placement on Patient Trust and Disease Stigma","The Impact of Hand Rub Placement on Hand Hygiene Sequence, Patient Trust, and Disease Stigma: A Randomised Controlled Trial","Inclusion Criteria:\n\nFor Patients:\n\n* Aged 18 years or older.\n* Diagnosed with psoriasis and receiving treatment at the designated psoriasis specialty outpatient clinic during the study period.\n* Legally capable of signing the informed consent form and cognitively able to understand and complete the questionnaire (independently or with assistance from family members).\n\nFor Physicians:\n\n* Hold a registered practicing qualification in the Dermatology Department of Huashan Hospital Pudong Branch and are qualified for independent outpatient consultations.\n* Scheduled to continuously undertake outpatient work in the designated consultation rooms during the study period.\n* Voluntarily sign the informed consent form for behavioral observation.\n\nExclusion Criteria:\n\nFor Patients:\n\n* Severe visual, hearing, or speech impairments leading to basic doctor-patient communication barriers.\n* Diagnosed with psychiatric disorders (e.g., schizophrenia, severe depression) that, as assessed by a specialist, may interfere with the authenticity of the questionnaire responses.\n* Presenting with a clinical state requiring emergency treatment during the visit, such as acute infection of skin lesions or generalized pustules.\n\nFor Physicians:\n\n* Non-permanent practicing staff of the hospital, such as visiting physicians or rotating medical students.\n* Unable to independently perform hand hygiene procedures due to physical\u002Flimb dysfunction.",{"count":511,"type":22},250,[136],"This study aims to investigate how the physical placement of hand sanitizer in consultation rooms affects patient trust and feelings of disease stigma. While hand hygiene is an essential infection control measure in healthcare, performing it immediately in front of patients with visible, non-communicable conditions (such as psoriasis) might inadvertently make patients feel rejected or stigmatized.This study uses a randomized controlled design to evaluate if a simple environmental modification-changing the spatial location of the hand sanitizer-can naturally nudge physicians to alter their hand hygiene timing without compromising safety. Researchers will discreetly observe the hand hygiene behavior of outpatient dermatologists and ask participating psoriasis patients to complete a brief, anonymous questionnaire regarding their trust in the physician, feelings of stigma, and overall satisfaction with the consultation. The goal is to provide evidence for patient-centered hospital space designs that protect patient psychological well-being while maintaining hygiene standards.",[515,516],"Noncommunicable Disease","Psoriasis","2026-04-20",{"date":519,"type":34},"2026-04-27",{"date":521,"type":22},"2026-05-01",{"date":395,"type":22},{"name":40,"class":41},{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":23,"phases":532,"briefSummary":533,"conditions":534,"keywords":536,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":66},"100634318","early-phase-1-evaluating-safety-tolerability-and-preliminary-efficacy-of-ysch-01-monotherapy-and-in-combination-with-atezolizumab-for-recurrent-glioblastoma-100634318","NCT07538128","Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma","An Open-Label, Single-Center, Multiple-Dose Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab in the Treatment of Recurrent Glioblastoma","Inclusion Criteria\n\nParticipants must meet all the following criteria to be enrolled in this study:\n\n1. Age \\> 18 years, male or female.\n2. Expected survival ≥ 12 weeks.\n3. Karnofsky Performance Status (KPS) score ≥ 70 at baseline.\n4. Histopathologically confirmed glioblastoma (GBM), with first recurrence after prior surgery, chemotherapy, and\u002For radiotherapy.\n5. Presence of 1 contrast-enhancing tumor lesion (diameter 1-4 cm) assessed by MRI during the screening phase.\n6. Eligibility for tumor biopsy and Ommaya reservoir implantation based on hematological, hepatic, renal, and coagulation function parameters.\n7. Recovery from toxic effects of prior chemo\u002Fradiotherapy (CTCAE ≤ Grade 1, except for special cases like alopecia or pigmentation), with the Investigator determining that the corresponding adverse events (AEs) pose no safety risk.\n8. Eligible subjects of reproductive potential (male and female) must agree to use effective contraception during the trial and for at least 6 months after the last dose.\n\nExclusion Criteria\n\nParticipants with any of the following conditions are ineligible for enrollment:\n\n1. History or current evidence of another primary malignancy.\n2. Known allergy to the study drug or any of its excipients, or a history of unexplained severe allergic reactions.\n3. Any contraindication to gadolinium-enhanced MRI, such as presence of a pacemaker, infusion pump, or allergy to MRI contrast agents.\n4. Tumor involvement of the brainstem, cerebellum, or spinal cord; or leptomeningeal disease.\n5. MRI evidence of tumor enhancement extending to the ventricular wall, or the tumor cavity is fused with the ventricle after surgery.\n6. Preoperative MRI assessment showing the Ommaya puncture path traverses the ventricles.\n7. Active infection requiring intravenous antibiotic therapy, or unexplained fever (body temperature ≥37.5°C).\n8. Uncontrolled systemic diseases or relevant medical history, including: diabetes mellitus, cardiovascular\u002Fcerebrovascular disease (e.g., heart failure ≥NYHA Class II, hypertension ≥Grade 2, ≥First-degree atrioventricular block, history of myocardial infarction, myocarditis), pulmonary insufficiency, thyroid dysfunction, cerebral infarction within the past 6 months.\n9. Active autoimmune disease or history of autoimmune disorders (e.g., ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, autoimmune vasculitis, Wegener's granulomatosis).\n10. Plan or requirement to receive any live vaccine during the screening or treatment phase.\n11. Other conditions assessed as incompatible with intravenous administration of Atezolizumab.",{"count":262,"type":22},[264],"The clinical study of YSCH-01 will adopt an open-label, randomized design, with a planned enrollment of 10 participants with recurrent glioblastoma. Participants will be randomly allocated to the YSCH-01 monotherapy cohort or the YSCH-01 + Atezolizumab combination cohort, with 5 participants in each cohort. The study consists of the following three phases: screening phase, treatment phase, and follow-up phase. The primary endpoint is the 1-year survival rate of participants",[535],"Recurrent Glioblastoma",[537,535,538,539],"YSCH-01","Adenovirus","Atezolizumab","2026-04-13",{"date":517,"type":34},{"date":543,"type":34},"2025-01-09",{"date":545,"type":22},"2027-02-28",{"name":40,"class":41},{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":132,"enrollmentInfo":554,"targetDuration":4,"studyType":23,"phases":555,"briefSummary":556,"conditions":557,"keywords":560,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":66},"100630003","phase-2-sglt2i-improve-left-atrial-function-in-patients-with-paroxysmal-atrial-fibrillation-hypertension-and-abnormal-glucose-metabolism-100630003","NCT07482020","SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism","A Randomized Controlled Trial of SGLT2 Inhibitors to Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation and Comorbid Hypertension and Abnormal Glucose Metabolism","Inclusion Criteria:\n\n* • Patients aged 18-80 years, treated in the outpatient or inpatient departments of each research center and included in the AF database.\n\n  * Patients with paroxysmal AF confirmed by 12-lead electrocardiogram, 24-hour Holter monitoring, or handheld electrocardiogram devices.\n  * Patients with hypertension who have already started antihypertensive treatment.\n  * Patients with diabetes who have already started antidiabetic treatment, or patients with prediabetes who have not received antidiabetic treatment but have an HbA1c level within the range of 6.1-6.4% in the past three months.\n\nExclusion Criteria:\n\n* • Atrial fibrillation caused by severe mitral stenosis.\n\n  * Atrial fibrillation with severe mitral regurgitation and severe tricuspid regurgitation.\n  * Patients who have been clinically diagnosed with heart failure (heart failure with preserved ejection fraction or heart failure with reduced ejection fraction).\n  * Special types of cardiomyopathy: amyloid cardiomyopathy, Fabry disease, muscular dystrophy, hypertrophic obstructive cardiomyopathy, etc.\n  * Patients with a history of myocardial infarction within the past three months.\n  * Pregnant women.",{"count":254,"type":22},[25],"Heart failure is the most important clinical endpoint event in atrial fibrillation (AF). Patients with AF complicated by heart failure have a significantly higher risk of all-cause mortality and cardiovascular mortality compared to those without heart failure. Abnormal left atrial function is an important mechanism leading to the occurrence of AF-related heart failure. Therefore, it is essential to find drugs that can improve left atrial function to prevent heart failure in patients with AF. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are important drugs for regulating metabolic abnormalities. Studies have found that these drugs also reduce the risk of new-onset AF in patients with heart failure. Thus, the investigators hypothesize that SGLT2i may be able to regulate left atrial function.\n\nThis study is a multicenter randomized controlled trial using three-dimensional speckle tracking echocardiography to investigate whether SGLT2i can improve left atrial function and prevent heart failure in patients with paroxysmal AF who have hypertension and metabolic disorders, compared to placebo. The investigators also observed the effects of SGLT2i on cardiovascular and metabolic risk factors. The investigator team has a solid foundation in the field of cardiovascular metabolism, having completed the evaluation of left atrial function in paroxysmal AF using three-dimensional speckle tracking technology over the past three years. This study is the first to propose that SGLT2i can improve left atrial function in paroxysmal AF patients with metabolic abnormalities, which is of great significance for preventing heart failure in this type of AF.",[558,559],"Atrial Fibrillation (AF)","Hypertension",[561,562,563],"SGLT2 inhibitor","atrial fibrillation","hypertension","2026-03-15",{"date":566,"type":34},"2026-03-19",{"date":568,"type":34},"2025-03-01",{"date":570,"type":22},"2027-06-30",{"name":40,"class":41},{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":577,"acronym":578,"eligibilityCriteria":579,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":23,"phases":581,"briefSummary":582,"conditions":583,"keywords":586,"overallStatus":195,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":597,"locationsCount":66},"100629060","vorasidenib-guided-by-agx-pet-in-recurrentlow-grade-glioma-100629060","NCT07469735","Vorasidenib Guided by AGX PET in Recurrent\u002FLow-grade Glioma","18F-AGX PET for Evaluation of Vorasidenib Response and Tumor Metabolic Changes in Low-grade IDH-Mutant Glioma","VANGUARD","Inclusion Criteria:\n\n1. Histologically or molecularly confirmed WHO 2021 grade 2 or 3 IDH1\u002F2-mutant diffuse glioma with recurrent or residual disease\n2. At least one measurable non-enhancing lesion (≥1 cm × ≥1 cm) on postoperative T2\u002FFLAIR MRI\n3. Eligible for Vorasidenib treatment\n4. Age ≥18 years\n5. Karnofsky Performance Status (KPS) score ≥80\n6. Adequate hematologic function\n7. Adequate renal function\n8. Adequate hepatic function\n9. Ability to provide written informed consent\n\nExclusion Criteria:\n\n1. Prior treatment with radiotherapy, chemotherapy, or IDH inhibitors\n2. Known contraindications to Vorasidenib\n3. Contraindications to PET\u002FCT imaging\n4. Uncontrolled hyperglycemia\n5. Pregnancy or breastfeeding\n6. Inability to undergo repeated intravenous injections\n7. Known hypersensitivity to imaging agents or study-related medications\n8. Use of strong CYP1A2 inhibitors or CYP2C19 or CYP3A substrates with narrow therapeutic index\n9. Any serious comorbid condition that may interfere with study participation or safety",{"count":262,"type":22},[136],"The goal of this prospective, single-arm, open-label clinical trial is to evaluate whether 18F-AGX PET imaging can be used to assess early treatment response and metabolic changes in adult patients with recurrent or residual WHO 2021 grade 2-3 IDH-mutant diffuse glioma receiving Vorasidenib therapy.\n\nIDH-mutant diffuse gliomas often show slow tumor growth, making early treatment response difficult to evaluate using conventional structural imaging such as magnetic resonance imaging (MRI). Clinical endpoints such as progression-free survival (PFS) and overall survival (OS) typically require long follow-up periods to detect treatment effects. Therefore, the development of sensitive and noninvasive imaging methods for early evaluation of therapeutic response is needed.\n\nThis study aims to determine whether metabolic changes detected by 18F-AGX PET during Vorasidenib treatment are associated with tumor structural changes and clinical outcomes.\n\nThe main questions it aims to answer are:\n\n* Whether early changes in tumor metabolic activity measured by 18F-AGX PET, including percentage change in maximum tumor-to-background ratio (TBRmax), are associated with changes in tumor growth rate (TGR) measured by MRI during treatment.\n* Whether early metabolic response detected by 18F-AGX PET imaging after initiation of Vorasidenib treatment can predict subsequent disease progression or tumor growth dynamics.\n\nParticipants enrolled in this study will receive oral Vorasidenib once daily for 12 treatment cycles (28 days per cycle), with dosing based on body weight.\n\nParticipants will:\n\n* Undergo baseline MRI and 18F-AGX PET imaging following surgery for recurrent or residual disease.\n* Receive oral Vorasidenib continuously for 12 cycles.\n* Undergo MRI scans at baseline and during treatment cycles 1, 2, 3, 6, 9, and 12 to assess structural tumor changes.\n* Undergo 18F-AGX PET\u002FCT scans at baseline and during treatment cycles 1, 2, 3, 6, and 12 to assess metabolic tumor activity.\n* Provide serial blood samples for laboratory safety monitoring, including hematologic and biochemical testing.\n* Undergo magnetic resonance spectroscopy (MRS) to quantify intratumoral 2-hydroxyglutarate (2-HG) levels as an indicator of IDH mutation-associated metabolic activity.\n\nParticipants will be followed for imaging-based disease progression using RANO criteria and for treatment-related adverse events during the study period.\n\nThis study will evaluate the feasibility of using 18F-AGX PET imaging as a noninvasive imaging biomarker for early response assessment in IDH-mutant diffuse glioma patients receiving targeted IDH inhibition therapy with Vorasidenib.",[184,584,585],"Diffuse Glioma","Recurrent Gliomas",[587,588,589,590],"IDH Mutation","Vorasidenib","Positron Emission Tomography","Treatment Response","2026-03-09",{"date":593,"type":34},"2026-03-13",{"date":595,"type":22},"2026-04-01",{"date":123,"type":22},{"name":40,"class":41},{"id":599,"slug":600,"hasResults":12,"nctId":601,"briefTitle":602,"officialTitle":603,"acronym":604,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":17,"minAge":606,"maxAge":132,"enrollmentInfo":607,"targetDuration":4,"studyType":23,"phases":609,"briefSummary":610,"conditions":611,"keywords":612,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":622,"locationsCount":623},"100527846","phase-4-asymptomatic-tb-with-innovative-modified-short-course-regimens-100527846","NCT06153069","Asymptomatic TB With Innovative Modified Short-course Regimens","Clinical Efficacy of a Short-course Regimen for Asymptomatic Tuberculosis in China","SWIFT","Inclusion Criteria:\n\n* 1\\. Age between 14 to 80 years;\n* 2\\. Male or female;\n* 3\\. Willing to provide signed informed consent, or parental consent and participant assent;\n* 4\\. Individuals with respiratory tract specimen (including sputum\u002Fbronchoalveolar lavage fluid\u002Flung tissue) positive for acid-fast bacilli smear\u002Fculture\u002Fmolecular amplification for M. tuberculosis;\n* 5\\. No unexplained TB-suggestive symptoms in the three months prior to screening, including cough lasting more than two weeks, night sweats, fever or weight loss;\n* 6\\. If non-menopausal woman, agree to use or have used effective contraception during treatment.\n\nExclusion Criteria:\n\n* 1\\. Combined extrapulmonary tuberculosis;\n* 2\\. Induviduals with extensive lesion (lesion involvement exceeding 50% or the aggregate diameter of all cavities exceeding 6 cm) ;\n* 3\\. Individuals will be excluded from enrollment if, at the time of enrollment, their M. tuberculosis isolate is already known to be resistant to any one or more of the following: rifampin, isoniazid, pyrazinamide, ethambutol, or fluoroquinolones;\n* 4\\. Individuals with impaired liver function (alanine transaminase \\[ALT\\] or total bilirubin \\[TBIL\\] more than 2.5 times the upper limit of normal) or combined with liver cirrhosis;\n* 5\\. Hemoglobin is less than 70g\u002FL, or platelet is less than 50\\*10\\^9\u002FL;\n* 6\\. Estimated Glomerular Filtration Rate (eGFR) is less than 30 mL\u002Fmin\u002F1.73m2;\n* 7\\. Known allergic or intolerant to any of the study drugs;\n* 8\\. Pregnant or breast-feeding;\n* 9\\. Prior anti-TB treatment for more than one week in the past six months;\n* 10.Known history of epilepsy, uncontrolled diabetes;\n* 11.For HIV-positive subjects, T-lymphocyte (CD4 cell) counts less than 100 cells\u002Fmm3;\n* 12\\. Unable to tolerant oral treatment.","14 Years",{"count":608,"type":22},426,[78],"This study is a randomized controlled trial among asymptomatic tuberculosis individuals aiming to assess whether the standard treatment duration can be shortened to 17 weeks without increasing the types or doses of anti-tuberculosis medications or 13 weeks with the high-dose rifapentine and moxifloxacin.",[242],[613,614],"subclinical tuberculosis","shorter treatment","2026-02-08",{"date":617,"type":34},"2026-02-11",{"date":619,"type":34},"2025-11-21",{"date":621,"type":22},"2028-11",{"name":40,"class":41},5,""]